Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.

Li M, Spakowicz D, Burkart J, Patel S, Husain M, He K, Bertino EM, Shields PG, Carbone DP, Verschraegen CF, Presley CJ, Otterson GA, Kendra K, Owen DH.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2541-2546. doi: 10.1007/s00432-019-02982-4. Epub 2019 Jul 31.

2.

Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins.

Averill AM, Rehman HT, Charles JW, Dinh TA, Danyal K, Verschraegen CF, Stein GS, Dostmann WR, Ramsey JE.

J Cell Biochem. 2019 Aug;120(8):13783-13791. doi: 10.1002/jcb.28651. Epub 2019 Apr 2.

PMID:
30938854
3.

Novel organometallic chloroquine derivative inhibits tumor growth.

Hall EA, Ramsey JE, Peng Z, Hayrapetyan D, Shkepu V, O'Rourke B, Geiger W, Lam K, Verschraegen CF.

J Cell Biochem. 2018 Jul;119(7):5921-5933. doi: 10.1002/jcb.26787. Epub 2018 Mar 25.

PMID:
29575007
4.

Breast cancer screening in patients with cancers other than breast.

Leopold RB, Thomas AW, Concannon KF, Correll AD, LaPenta CM, Maurer SM, Sprague BL, Herschorn SD, Verschraegen CF.

Breast Cancer Res Treat. 2017 Jun;163(2):343-348. doi: 10.1007/s10549-017-4179-7. Epub 2017 Mar 6.

5.

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB.

Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. doi: 10.1007/s00280-016-3205-5. Epub 2017 Jan 17.

PMID:
28097385
6.

When Clinical Trial Participation Is Not an Option in the Era of Personalized Medicine: The Case of Two Patients.

Verschraegen CF, Rehman H, Pulluri B, DeKay J, Barry M, Folefac E, Dittus K, Holmes C, Sprague J, Ades S, Gibson PC.

Oncology. 2017;92(1):55-60. doi: 10.1159/000450712. Epub 2016 Nov 8.

PMID:
27820931
7.

Reply to M.C. Chamberlain and T.J. Kruser.

Verschraegen CF, Thomas A, Vinh-Hung V.

J Clin Oncol. 2016 May 20;34(15):1827-8. doi: 10.1200/JCO.2016.66.6248. Epub 2016 Mar 14. No abstract available.

PMID:
26976409
8.

The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers.

Schott AF, Welch JJ, Verschraegen CF, Kurzrock R.

Semin Oncol. 2015 Oct;42(5):731-9. doi: 10.1053/j.seminoncol.2015.07.010. Epub 2015 Jul 10. Review.

9.

A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers.

Bauman J, Shaheen M, Verschraegen CF, Belinsky SA, Houman Fekrazad M, Lee FC, Rabinowitz I, Ravindranathan M, Jones DV Jr.

Transl Oncol. 2014 Apr 17. pii: S1936-5233(14)00020-5. doi: 10.1016/j.tranon.2014.03.001. [Epub ahead of print]

10.

Prognosis of hepatoid yolk sac tumor in women: what's up, Doc?

Rittiluechai K, Wilcox R, Lisle J, Everett E, Wallace HJ 3rd, Verschraegen CF.

Eur J Obstet Gynecol Reprod Biol. 2014 Apr;175:25-9. doi: 10.1016/j.ejogrb.2013.12.029. Epub 2014 Jan 3. Review.

PMID:
24462393
11.

A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma.

Verschraegen CF, Movva S, Ji Y, Schmit B, Quinn RH, Liem B, Bocklage T, Shaheen M.

Cancers (Basel). 2013 Apr 11;5(2):418-29. doi: 10.3390/cancers5020418.

12.

New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R.

Am J Pathol. 2013 Apr;182(4):1065-77. doi: 10.1016/j.ajpath.2012.12.028. Epub 2013 Feb 8. Review.

13.

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.

Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, Pothuri B, Eberhardt S, Muggia F.

Ann Oncol. 2012 Dec;23(12):3104-10. doi: 10.1093/annonc/mds172. Epub 2012 Jul 31.

14.

Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.

Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara DR.

J Thorac Oncol. 2011 Nov;6(11):1938-45. doi: 10.1097/JTO.0b013e318229586e.

15.

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T.

Ann Oncol. 2012 Mar;23(3):785-90. doi: 10.1093/annonc/mdr299. Epub 2011 Jul 11.

16.

Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.

Movva S, Verschraegen CF, Rabinowitz I, Mangalik A, Parks V, Lee FC.

Melanoma Res. 2011 Feb;21(1):76-9. doi: 10.1097/CMR.0b013e32833d3293.

PMID:
21169871
17.

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.

Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA.

J Clin Oncol. 2010 Oct 10;28(29):4513-20. doi: 10.1200/JCO.2009.26.9696. Epub 2010 Sep 13.

18.

Negotiating for success: navigating the contracting process for an exemplary research program.

Baer AR, Hohneker JA, Stewart TL, Verschraegen CF.

J Oncol Pract. 2010 Mar;6(2):107-10. doi: 10.1200/JOP.091082.

19.

A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.

Fekrazad HM, Verschraegen CF, Royce M, Smith HO, Chyi Lee F, Rabinowitz I.

Am J Clin Oncol. 2010 Aug;33(4):393-7. doi: 10.1097/COC.0b013e3181b2043f.

PMID:
19884803
20.

Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.

Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF.

Gynecol Oncol. 2009 Sep;114(3):480-5. doi: 10.1016/j.ygyno.2009.05.045. Epub 2009 Jun 27.

21.

GPR30 predicts poor survival for ovarian cancer.

Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER.

Gynecol Oncol. 2009 Sep;114(3):465-71. doi: 10.1016/j.ygyno.2009.05.015. Epub 2009 Jun 6.

22.

Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.

Mita M, Mita A, Sarantopoulos J, Takimoto CH, Rowinsky EK, Romero O, Angiuli P, Allievi C, Eisenfeld A, Verschraegen CF.

Cancer Chemother Pharmacol. 2009 Jul;64(2):287-95. doi: 10.1007/s00280-008-0869-5. Epub 2008 Nov 25.

PMID:
19034451
23.

A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.

Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB.

Cancer Chemother Pharmacol. 2009 Apr;63(5):903-10. doi: 10.1007/s00280-008-0813-8. Epub 2008 Aug 6.

PMID:
18682950
24.

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL.

J Clin Oncol. 2008 Jul 20;26(21):3567-72. doi: 10.1200/JCO.2007.15.2868.

PMID:
18640937
25.

Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.

Lee SJ, Gounder M, Rubin EH, Li JM, Gu Z, Thalasila A, Loyer E, Kudelka AP, Verschraegen CF.

Invest New Drugs. 2008 Dec;26(6):541-51. doi: 10.1007/s10637-008-9147-y. Epub 2008 Jul 4.

PMID:
18600301
26.

SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.

Mills DA, Fekrazad HM, Verschraegen CF.

Curr Opin Investig Drugs. 2008 Jun;9(6):647-57. Review.

PMID:
18516764
27.

Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.

Pacheco AV, Rasila K, Lee SJ, Rabinowitz I, Elias L, Lee FC, Verschraegen CF.

Urol Oncol. 2008 Nov-Dec;26(6):610-5. doi: 10.1016/j.urolonc.2007.09.001. Epub 2008 Mar 4.

PMID:
18367103
28.

Absence of epidermal growth factor receptor mutations in cervical cancer.

Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, Verschraegen CF.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54. Epub 2007 Oct 19.

PMID:
17949425
29.

Changing trends in gestational trophoblastic disease.

Smith HO, Wiggins C, Verschraegen CF, Cole LW, Greene HM, Muller CY, Qualls CR.

J Reprod Med. 2006 Oct;51(10):777-84.

PMID:
17086806
30.

Incidence and survival rates for female malignant germ cell tumors.

Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, Qualls CR.

Obstet Gynecol. 2006 May;107(5):1075-85.

PMID:
16648414
31.

Malignant adnexal masses in pregnancy.

Sayar H, Lhomme C, Verschraegen CF.

Obstet Gynecol Clin North Am. 2005 Dec;32(4):569-93. Review.

PMID:
16310673
32.

Alternative administration of camptothecin analogues.

Glaberman U, Rabinowitz I, Verschraegen CF.

Expert Opin Drug Deliv. 2005 Mar;2(2):323-33. Review.

PMID:
16296757
33.

Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer.

Hu W, Kavanagh JJ, Deaver M, Johnston DA, Freedman RS, Verschraegen CF, Sen S.

Oncol Res. 2005;15(1):49-57.

PMID:
15839305
34.

TLK-286.

Verschraegen CF, Smith HO, Lee FC, Cathcart C, Norenberg JP.

IDrugs. 2004 Aug;7(8):771-81. Review.

PMID:
15334311
35.

Gestational trophoblastic neoplasia in American Indians.

Smith HO, Qualls CR, Hilgers RD, Verschraegen CF, Rayburn WF, Cole LW, Padilla LA, Key CR.

J Reprod Med. 2004 Jul;49(7):535-44.

PMID:
15305825
37.

Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies.

Verschraegen CF, Gilbert BE, Loyer E, Huaringa A, Walsh G, Newman RA, Knight V.

Clin Cancer Res. 2004 Apr 1;10(7):2319-26.

38.

Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.

Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF.

Cancer Invest. 2003;21(5):682-9.

PMID:
14628425
39.

Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor.

Hu W, Wu W, Verschraegen CF, Chen L, Mao L, Yeung SC, Kudelka AP, Freedman RS, Kavanagh JJ.

Proteomics. 2003 Oct;3(10):1904-11.

PMID:
14625852
40.

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.

Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R.

Cancer Chemother Pharmacol. 2004 Jan;53(1):1-7. Epub 2003 Oct 28.

PMID:
14586557
41.

Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.

Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH.

J Cancer Res Clin Oncol. 2003 Oct;129(10):549-55. Epub 2003 Aug 29.

PMID:
14513369
42.

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Völker P, Kavanagh J, Steger M, Schulz KD, Emons G.

Gynecol Oncol. 2003 Sep;90(3):552-9.

PMID:
13678723
43.

KW-2170 (Kyowa Hakko Kogyo).

Verschraegen CF.

IDrugs. 2002 Oct;5(10):1000-3.

PMID:
12800063
44.

Diagnosis, staging, and surveillance of cervical carcinoma.

Kaur H, Silverman PM, Iyer RB, Verschraegen CF, Eifel PJ, Charnsangavej C.

AJR Am J Roentgenol. 2003 Jun;180(6):1621-31. Review. No abstract available.

PMID:
12760933
45.

Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.

Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC.

Clin Cancer Res. 2003 Feb;9(2):845-52.

46.

Irinotecan for the treatment of cervical cancer.

Verschraegen CF.

Oncology (Williston Park). 2002 May;16(5 Suppl 5):32-4. Review.

47.

Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.

Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger B.

Lancet. 2002 Jun 22;359(9324):2145-52.

PMID:
12090979
48.

Intracavitary therapies for mesothelioma.

Verschraegen CF.

Curr Treat Options Oncol. 2001 Oct;2(5):385-94. Review.

PMID:
12057101
49.

Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor.

Hu W, Wu W, Yeung SC, Freedman RS, Kavanagh JJ, Verschraegen CF.

Anticancer Res. 2002 Mar-Apr;22(2A):665-72.

PMID:
12014635
50.

Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines.

Hu W, Verschraegen CF, Wu WG, Nash M, Freedman RS, Kudelka A, Kavanagh JJ.

Int J Gynecol Cancer. 2002 Mar-Apr;12(2):202-7.

PMID:
11975681

Supplemental Content

Loading ...
Support Center